Dear friends of MVMD,
This morning we announced the appointment of five additional advisors to MVMD, and I wanted to provide some further context on why I believe these appointments are important and how they fit within the broader direction of the Company. If you did not get a chance to see the news release, you can access it HERE.
When we announced our first advisory group earlier this year, I explained that we were being intentional about strengthening the experience, capabilities and relationships surrounding MVMD. These latest appointments continue that process and add complementary experience across clinical and consumer health, regenerative agriculture, strategic communications, technology, intellectual property, governance, international business development and U.S. capital markets.
As I said at the time, advisors do not build businesses. Our management team remains responsible for execution, commercial discipline and delivering results. However, the right people around the table can improve the quality of our decisions, help us identify and access relevant opportunities, and increase the speed at which important relationships can be developed.
This group was selected with those objectives in mind. Dr. Zach Bush and Dr. Sanjeev Goel bring extensive experience across clinical medicine, consumer health, longevity, food systems and the relationship between human and planetary health. Erai Beckmann adds international commercialization, regulatory and emerging technology experience. Mehcad Brooks brings a combination of entrepreneurship, media, technology and engagement with global audiences. Eric Zember adds substantial experience across intellectual property, technology transactions, governance and strategic growth.
Collectively, these individuals add important capabilities to the advisory group announced in April. The combined group now surrounds MVMD with experience spanning formulation science, regulatory strategy, clinical and consumer health, agriculture, manufacturing, commercialization, communications, intellectual property, business development and capital markets.
There is a deliberate progression behind this.
For much of MVMD’s history, our work was naturally focused on developing, testing and validating our technologies. That foundational work remains critical, but the next stage requires us to increasingly convert those assets into commercial partnerships, licensed products and scalable revenue opportunities. The capabilities required also evolve as a business moves from technology development toward broader commercialization.
In human health, Quicksome™ continues to progress from individual product applications toward a broader delivery platform with potential across nutraceuticals, compounded pharmacy products, peptides and other bioactive molecules. In agriculture, Agrarius™ has generated encouraging field validation across multiple crops and regions, while creating opportunities within regenerative agriculture, food systems and broader biological performance. We are also continuing to build relationships and capabilities that support stronger U.S. business development and prepare the Company for the capital markets opportunities we continue to evaluate.
The pattern across these activities is intentional. MVMD is no longer being developed around a single technology, product or market. We are building across human health, agriculture and broader opportunities where advanced technologies can improve health, performance, resilience and accessibility. It is increasingly important that our team, strategy and market positioning reflect the full scope of that work.
I believe MVMD is moving through an important period of evolution. Our commercial focus is becoming sharper, the capabilities surrounding the Company are becoming stronger, and the broader purpose connecting our work is becoming increasingly clear.
I am encouraged by the progress being made and by the increasing clarity around what MVMD is becoming. With the right people, a stronger foundation and a sharper commercial focus, I believe we are well positioned to convert the opportunities now in front of us into meaningful commercial progress.
Thank you, as always, for your continued support and belief in our vision of More Life. More Life has long been the vision connecting our work across human health, agriculture and biological performance. As the breadth of our opportunities continues to expand, that vision is becoming increasingly relevant to the future we are building.
---
Additional Advisors
Zach Bush, MD
Dr. Zach Bush is a triple board-certified physician in internal medicine, endocrinology and metabolism, and hospice and palliative care, and a recognized voice at the intersection of human and planetary health. He completed his residency in internal medicine and fellowship in endocrinology and metabolism at the University of Virginia Health System, where he also served as a clinical instructor. He later served as Associate Medical Director of Hospice of the Piedmont.
A physician, researcher, author and educator, Dr. Bush’s work focuses on the microbiome, chronic disease, food systems, soil health and regenerative agriculture. He is the founder of Seraphic Group and a co-founder of Farmer’s Footprint, a nonprofit organization that works with farmers, communities and industry to advance regenerative agriculture and strengthen the connections among soil health, food systems and human health. His commercial experience includes the ION line of microbiome-support products, while his broader work spans consumer health, agriculture, education and nonprofit initiatives addressing human and ecological health.
Erai Beckmann
Erai Beckmann is a serial entrepreneur, investor, operator and strategic advisor with more than two decades of experience building, scaling and commercializing ventures across health sciences, emerging technologies and international markets. He has founded, led and advised private and publicly traded companies, with experience spanning commercialization strategy, regulatory navigation, international expansion, strategic partnerships and capital-markets development.
Mr. Beckmann was an early participant in the global cannabinoid pharmaceutical industry and co-founded one of the first CBD pharmaceutical companies to legally import into Latin America. He worked with regulators, policymakers, physicians and industry stakeholders in connection with changes to Brazil’s medical CBD framework in 2015. He currently serves as Founding Partner of Peace Through Trade, a regulation-focused Layer 1 blockchain ecosystem integrating artificial intelligence and digital infrastructure, and as principal of a private family office focused on emerging technologies, sustainability and growth-stage businesses. In 2025, Peace Through Trade was recognized at the inaugural SDG Leaders Luncheon hosted by SDG News at United Nations Headquarters during the 80th United Nations General Assembly.
Mehcad Brooks
Mehcad Brooks is an actor, writer, director, poet, entrepreneur and media executive whose career spans acting, writing, directing, producing and the development of media and technology ventures. Born and raised in Austin, Texas, he studied at the University of Southern California’s School of Cinematic Arts before building a career across film, television, music and digital media.
Mr. Brooks is internationally recognized for his roles in Desperate Housewives, True Blood, Supergirl, Law & Order and the Mortal Kombat film franchise. Beyond acting, he is the founder of Defiant Media, MB Interactive and Meta Film Ventures, ventures focused on developing original content and applying artificial intelligence and emerging technologies within media. He also serves on the Advisory Board of the Center for World Philosophy & Religion and the board of The Peace Studio.
His work also includes advocacy focused on human potential, innovation and precision wellness, including the potential role of emerging health technologies in improving outcomes, expanding access and supporting human performance. His experience across these areas includes entrepreneurship, strategic partnerships, technology-focused business leadership and engagement with global audiences.
Sanjeev Goel, MD, FCFP (PC)
Dr. Sanjeev Goel is a Canadian family physician, entrepreneur, author and educator with more than 25 years of clinical experience. He received his medical degree from the University of Toronto and is certified in family medicine by the College of Family Physicians of Canada. He is the founder and CEO of Peak Human, a personalized health practice focused on longevity, preventative health and human performance. His professional experience includes family medicine, remote medical service in Himalayan communities and mindfulness education for healthcare professionals.
Dr. Goel’s work focuses on healthy aging and the relationship among physical, mental and emotional well-being. Through his clinical practice, educational programs, writing and speaking engagements, he has explored areas including mindfulness, hormesis, autophagy, biological rhythms and personalized longevity protocols. His broader experience spans clinical medicine, integrative and regenerative health, health technology and patient education.
Eric Zember
Eric Zember is a strategic advisor, technology executive and lawyer with experience spanning seed-stage companies to Fortune 40 enterprises. He currently serves as General Counsel of Affinity Solutions, a consumer intelligence and data analytics company, where he advises on strategic growth, partnerships, governance, artificial intelligence, financing and regulatory matters. Over his career, he has negotiated more than $1 billion in technology, artificial intelligence, intellectual property licensing, software-as-a-service and data transactions, including while serving in senior legal and strategic roles at SAP and Lowe’s Companies.
Zember is an experienced board member and advisor who previously served on the Board of Directors of The Explorers Club, an international scientific society, and was the youngest person elected to its Board in the organization’s history. His published research on memory and cognition has appeared in Memory & Cognition and in a volume published by the American Psychological Association. A graduate of the University of Pennsylvania Law School and Cornell University, his broader experience spans strategic partnerships, intellectual property commercialization, governance, technology transactions and growth strategy.
